Assessments of New Methods of Cancer Therapy

Abstract

The large number of potentially valuable anticancer agents, the necessity of evaluating several dosages and various combinations, and the number of patients required for valid comparative trials have made the National Cancer Institute's cooperative clinical investigational program an indispensable tool in the assessment of new therapies. In this development, care provided to patients with advanced cancer had been considerably improved.